#1 Clinical Trials Search in Europe

Obexelimab

Obexelimab is an innovative monoclonal antibody currently being studied in clinical trials for various autoimmune disorders. This article explores the ongoing research on Obexelimab, focusing on its potential benefits for patients with conditions such as Warm Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus, Relapsing Multiple Sclerosis, and IgG4-Related Disease. These trials aim to evaluate the drug’s efficacy and safety in managing these challenging autoimmune conditions.

Table of Contents

What is Obexelimab?

Obexelimab is a new medication being studied for the treatment of various autoimmune diseases. It is classified as a monoclonal antibody, which is a type of protein designed to target specific cells in the body[1]. Monoclonal antibodies are often used in modern medicine to treat a variety of conditions, including autoimmune disorders and certain types of cancer.

How Does Obexelimab Work?

Obexelimab works in a unique way by targeting two specific proteins in the body simultaneously:

  1. CD19: This is a protein found on the surface of B cells, which are a type of white blood cell involved in the immune system.
  2. FcγRIIb (also written as FcyRIIb): This is a receptor that helps regulate immune responses.

By binding to both of these proteins at the same time, obexelimab helps to reduce the activity of B cells[2]. This is important because overactive B cells are often involved in autoimmune diseases, where the immune system mistakenly attacks the body’s own tissues.

Conditions Treated with Obexelimab

Obexelimab is being studied for the treatment of several autoimmune conditions, including:

  • Warm Autoimmune Hemolytic Anemia (wAIHA): A condition where the immune system destroys red blood cells, leading to anemia[1].
  • Systemic Lupus Erythematosus (SLE): A complex autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, and other organs[2].
  • Relapsing Multiple Sclerosis (RMS): A neurological condition where the immune system attacks the protective covering of nerves in the brain and spinal cord[3].
  • IgG4-Related Disease (IgG4-RD): A chronic inflammatory condition that can affect multiple organs in the body[4].

Current Clinical Trials

Obexelimab is currently being studied in several clinical trials to evaluate its effectiveness and safety:

  • SApHiAre Study: A Phase 3 trial for patients with Warm Autoimmune Hemolytic Anemia[1].
  • Systemic Lupus Erythematosus Study: A Phase 2 trial for patients with SLE[2].
  • MoonStone Study: A Phase 2 trial for patients with Relapsing Multiple Sclerosis[3].
  • INDIGO Study: A Phase 3 trial for patients with IgG4-Related Disease[4].

How is Obexelimab Administered?

In the clinical trials, obexelimab is administered as a subcutaneous injection. This means the medication is injected just under the skin, typically in areas such as the abdomen or thigh. The frequency of injections varies depending on the specific study and condition being treated, but it is often given weekly or every two weeks[1][2][3][4].

Potential Benefits of Obexelimab

While the full benefits of obexelimab are still being studied, researchers are looking at several potential positive outcomes, including:

  • Improved hemoglobin levels in patients with wAIHA[1].
  • Reduced disease activity in patients with SLE[2].
  • Decreased number of new brain lesions in patients with RMS[3].
  • Prevention of disease flares in patients with IgG4-RD[4].

Safety Considerations

As with any new medication, the safety of obexelimab is being closely monitored in clinical trials. Researchers are paying particular attention to:

  • Adverse events (side effects) that may occur during treatment.
  • Injection site reactions, which are common with subcutaneous medications.
  • Potential hypersensitivity reactions (allergic reactions).
  • Any serious adverse events that may occur[3].

It’s important to note that obexelimab is still an investigational drug, which means it has not yet been approved for general use by regulatory agencies like the FDA. Patients interested in this treatment should discuss the potential risks and benefits with their healthcare provider and consider participating in clinical trials if appropriate.

Condition Trial Phase Primary Outcome Duration
Warm Autoimmune Hemolytic Anemia (wAIHA) Phase 3 Proportion of participants with durable hemoglobin response 81 weeks
Systemic Lupus Erythematosus (SLE) Phase 2 Proportion of patients achieving BICLA response 40 weeks
Relapsing Multiple Sclerosis (RMS) Phase 2 Cumulative number of new GdE T1 hyperintense lesions 92 weeks
IgG4-Related Disease (IgG4-RD) Phase 3 Time to first IgG4-RD flare 172 weeks

FAQ

  • What is Obexelimab and how does it work? Obexelimab is a monoclonal antibody that simultaneously binds to CD19 and FcγRIIb proteins on B cells. This unique mechanism helps to reduce B cell activity, which is often overactive in autoimmune disorders. By regulating B cell function, Obexelimab may help control the immune system's attack on the body's own tissues.
  • What conditions are being studied in Obexelimab clinical trials? Current clinical trials are investigating Obexelimab for several autoimmune disorders, including Warm Autoimmune Hemolytic Anemia (wAIHA), Systemic Lupus Erythematosus (SLE), Relapsing Multiple Sclerosis (RMS), and IgG4-Related Disease (IgG4-RD).
  • How is Obexelimab administered in these trials? In the clinical trials, Obexelimab is administered as a subcutaneous (SC) injection. The frequency of injections varies depending on the specific trial, but it is typically given weekly or at regular intervals as determined by the study protocol.
  • What are the primary outcomes being measured in these trials? The primary outcomes vary depending on the condition being studied. For example, in the wAIHA trial, researchers are looking at the proportion of participants who achieve a durable hemoglobin response. In the SLE trial, they're measuring the proportion of patients who achieve a response according to the BILAG-Based Composite Lupus Assessment. For RMS, they're tracking the number of new brain lesions, and for IgG4-RD, they're measuring the time to first disease flare.
  • How long do these clinical trials last? The duration of the trials varies, but they generally include a treatment period ranging from 24 to 52 weeks, followed by an open-label extension period and a follow-up period. The total duration of participation for patients can range from approximately 40 weeks to 172 weeks, depending on the specific trial.

Ongoing Clinical Trials on Obexelimab

  • Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark Finland +4

  • Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE)

    Not recruiting

    1 1
    Investigated drugs:
    Belgium Bulgaria Denmark Germany Greece Italy +4

  • Study on the Effects of Obexelimab for Patients with IgG4-Related Disease

    Not recruiting

    1 1
    Investigated drugs:
    France Germany Hungary Italy The Netherlands Poland +2

  • Study of Obexelimab for Patients with Warm Autoimmune Hemolytic Anemia

    Not recruiting

    1 1
    Investigated drugs:
    Italy Poland Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer and other diseases.
  • Autoimmune disorder: A condition in which the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage in various organs and systems.
  • Warm Autoimmune Hemolytic Anemia (wAIHA): A rare blood disorder where the immune system produces antibodies that destroy red blood cells, leading to anemia.
  • Systemic Lupus Erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • Relapsing Multiple Sclerosis (RMS): A form of multiple sclerosis characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • IgG4-Related Disease (IgG4-RD): A chronic inflammatory condition that can affect multiple organs, characterized by high levels of IgG4 antibodies and the formation of tumor-like masses.
  • Subcutaneous (SC) injection: A method of administering medication by injecting it into the layer of fat just beneath the skin.
  • Hemoglobin (Hgb): A protein in red blood cells that carries oxygen throughout the body. Hemoglobin levels are used to diagnose and monitor anemia.
  • BILAG-Based Composite Lupus Assessment (BICLA): A tool used to measure disease activity and response to treatment in patients with systemic lupus erythematosus.
  • Gadolinium-enhancing (GdE) T1 hyperintense lesions: Brain lesions visible on MRI scans that indicate active inflammation in multiple sclerosis patients.

References